Coronaviruses and the Cardiovascular System: Acute and Long-term Implications

Tian-Yuan Xiong; Simon Redwood; Bernard Prendergast; Mao Chen


Eur Heart J. 2020;41(19):1798-1800. 

In This Article

Does the Risk of Cardiovascular Disease Persist?

Heightened systemic inflammatory and pro-coagulant activity can persist in survivors of hospitalization for community-acquired pneumonia long after resolution of the index infection. The clinical effects of pneumonia have been linked to increased risk of cardiovascular disease up to 10-year follow-up[16] and it is likely that cases infected via respiratory virus outbreaks will experience similar adverse outcomes. Therapeutic use of corticosteroids further augments the possibility of adverse cardiovascular events. However, long-term follow-up data concerning the survivors of respiratory virus epidemics are scarce. Lipid metabolism remained disrupted 12 years after clinical recovery in a metabolomic study amongst 25 SARS survivors,[17] whereas cardiac abnormalities observed during hospitalisation in eight patients with H7N9 influenza returned to normal at 1-year follow-up.[18] Whilst viral phenotype, baseline clinical characteristics, initial disease severity, and immediate management impact on short-term survival, long-term prognosis following outbreaks of respiratory virus infection may equally depend upon the extra-pulmonary manifestations. Serial follow-up studies amongst the survivors of acute infection are sorely needed.